Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.57 |
| ▸ | ELANE | P08246 | 3/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990759 | 1.00 | CYP19A1 (0.57) | CYP19A1ELANEGRM2CTSGPRTN3 | |
| SCHEMBL24126788 | 0.90 | ELANE (0.56) | ELANEGRM2CTSGPRTN3PTGDR2 | |
| SCHEMBL984328 | 0.80 | CYP19A1 (0.52) | CYP19A1ELANECTSGPTGDR2GSK3A | |
| SCHEMBL41550 | 0.79 | MEN1 (0.50) | PTGDR2ALDH1A1GSK3AGSK3B | |
| SCHEMBL2257976 | 0.76 | ELANE (0.61) | ELANECTSGPRTN3PTGDR2NPSR1 | |
| SCHEMBL986554 | 0.76 | SLC6A2 (0.47) | CYP19A1ELANEGRM2PTGDR2 | |
| SCHEMBL14037658 | 0.75 | CYP19A1 (0.47) | CYP19A1ELANEGRM2TSHRCYP2C19 | |
| SCHEMBL7932603 | 0.74 | ELANE (0.57) | ELANECTSGPRTN3PTGDR2NPSR1 | |
| SCHEMBL8416125 | 0.73 | ELANE (0.55) | CYP19A1ELANECTSGPRTN3PTGDR2 | |
| SCHEMBL1352319 | 0.73 | ELANE (0.59) | ELANECTSGPRTN3NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| EP-2516392-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076678-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP19A1 356/4885ELANE 4135/4885GRM2 383/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP19A1 356/4885ELANE 4135/4885GRM2 383/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP19A1 356/4885ELANE 4135/4885GRM2 383/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP19A1 356/4885ELANE 4135/4885GRM2 383/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | CYP19A1 356/4885ELANE 4135/4885GRM2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.